(Q48606487)

13 February 2018

title

Guidelines for Bacteriophage Product Certification. (English)

1 reference

13 February 2018

1 reference

1

Alan Fauconnier

1 reference

13 February 2018

language of work or name

English

0 references

publication date

1 January 2018

1 reference

13 February 2018

Methods in Molecular Biology

published in

1 reference

13 February 2018

volume

1693

1 reference

13 February 2018

page(s)

253-268

1 reference

13 February 2018

Phage cocktails and the future of phage therapy

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

Phage therapy pharmacology phage cocktails.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

European regulatory conundrum of phage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

What are the limitations on the wider therapeutic use of phage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

Call for a dedicated European legal framework for bacteriophage therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

Bacteriophage therapy: a regulatory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

Proposal for new European pharmaceutical legislation to permit access to custom-made anti-sense oligonucleotide medicinal products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2F978-1-4939-7395-8_19

10.1007/978-1-4939-7395-8_19

21 January 2018

Identifiers

DOI

1 reference

13 February 2018

PubMed ID

29119445

1 reference

13 February 2018